Manufacture heat-stable, freeze-dried antivenom for cold-chain-free rural stocking

The proposal

Shift antivenom formulation from liquid (refrigeration-dependent) to lyophilised powder reconstituted at the bedside, enabling storage at ambient temperature at the front-line facilities closest to where bites occur.

Why it would work

Most snakebites happen far from hospitals, and most liquid antivenoms require an unbroken cold chain that rural settings cannot maintain — a core reason product is unavailable at the point of need. Freeze-dried formulations tolerate ambient storage for years, removing the refrigeration constraint and letting antivenom be pre-positioned at primary clinics and health posts rather than concentrated in referral hospitals.

Evidence

Lyophilised products are already in use: PANAF-Premium (Premium Serums & Vaccines, India) is a freeze-dried antivenom that does not require refrigeration and carries a multi-year shelf life, and has shown broad preclinical neutralization of East and Southern African venoms. Refrigeration dependence is repeatedly identified as a key access barrier in rural Africa (phys.org, 2019).

Implementation path

Qualify freeze-dried formulations of region-appropriate products; validate reconstitution with locally available clean water/saline and train front-line staff; pre-position stock at primary-care level with buffer stocks; pair with the procurement-financing solution so ambient stock is actually funded and replenished.

Trade-offs and limitations

Lyophilisation raises per-vial cost and reconstitution requires clean diluent and some training. Crucially, heat-stability solves availability, not efficacy — a freeze-dried product still only works if it is matched to the local snakes (see the efficacy sub-issue). Early field results for newer lyophilised products still need large-scale clinical confirmation, and some product data comes from manufacturers and should be treated as unverified until independently evaluated.